Abstract
Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. Hence, full knowledge of cardiovascular complications of chemotherapeutic agents, essential diagnostics tests to order, and appropriate management is paramount to oncologist, oncology pharmacists, and scientific clinical investigators. The aforementioned is particularly true in the current oncology era of plenteous early clinical trials studying several pathway/molecular-targeting agents with an increased cardiotoxic potential and the rapid expedited approval of those drugs by the FDA. Herein, we present a review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 186-200 |
| Number of pages | 15 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 126 |
| DOIs | |
| State | Published - Jun 1 2018 |
Fingerprint
Keywords
- Adverse effects
- Anthracyclines
- Antineoplastics
- Cardio-oncology
- Chemotherapy
- Heart failure
- Molecular targeted therapies
- Monoclonal antibodies
- Patient safety
- QTc prolongation
- Taxanes
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Hematology
- Oncology
- Geriatrics and Gerontology
Cite this
Cardiotoxic effects of chemotherapy : A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. / Babiker, Hani M.; McBride, Ali; Newton, Michael; Boehmer, Leigh M.; Drucker, Adrienne Goeller; Gowan, Mollie; Cassagnol, Manouchkathe; Camenisch, Todd D; Anwer, Faiz -; Hollands, James M.
In: Critical Reviews in Oncology/Hematology, Vol. 126, 01.06.2018, p. 186-200.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Cardiotoxic effects of chemotherapy
T2 - A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system
AU - Babiker, Hani M.
AU - McBride, Ali
AU - Newton, Michael
AU - Boehmer, Leigh M.
AU - Drucker, Adrienne Goeller
AU - Gowan, Mollie
AU - Cassagnol, Manouchkathe
AU - Camenisch, Todd D
AU - Anwer, Faiz -
AU - Hollands, James M.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. Hence, full knowledge of cardiovascular complications of chemotherapeutic agents, essential diagnostics tests to order, and appropriate management is paramount to oncologist, oncology pharmacists, and scientific clinical investigators. The aforementioned is particularly true in the current oncology era of plenteous early clinical trials studying several pathway/molecular-targeting agents with an increased cardiotoxic potential and the rapid expedited approval of those drugs by the FDA. Herein, we present a review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer.
AB - Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. Hence, full knowledge of cardiovascular complications of chemotherapeutic agents, essential diagnostics tests to order, and appropriate management is paramount to oncologist, oncology pharmacists, and scientific clinical investigators. The aforementioned is particularly true in the current oncology era of plenteous early clinical trials studying several pathway/molecular-targeting agents with an increased cardiotoxic potential and the rapid expedited approval of those drugs by the FDA. Herein, we present a review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer.
KW - Adverse effects
KW - Anthracyclines
KW - Antineoplastics
KW - Cardio-oncology
KW - Chemotherapy
KW - Heart failure
KW - Molecular targeted therapies
KW - Monoclonal antibodies
KW - Patient safety
KW - QTc prolongation
KW - Taxanes
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85045672835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045672835&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2018.03.014
DO - 10.1016/j.critrevonc.2018.03.014
M3 - Review article
C2 - 29759560
AN - SCOPUS:85045672835
VL - 126
SP - 186
EP - 200
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -